Core Viewpoint - Guardant Health, Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference, highlighting its role as a leading precision oncology company focused on cancer care and treatment [1][2]. Company Overview - Guardant Health is dedicated to transforming patient care and accelerating new cancer therapies through advanced blood and tissue tests, real-world data, and AI analytics [3]. - The company aims to improve outcomes across all stages of cancer care, including early screening, monitoring for recurrence, and treatment selection for advanced cancer patients [3]. - Founded in 2012, Guardant Health emphasizes its mission to guard wellness and extend the time individuals can live free from cancer [3].

Core Viewpoint - Guardant Health, Inc. has announced a proposed public offering of $250 million in common stock, with an additional option for underwriters to purchase up to $37.5 million more, subject to market conditions [1][3]. Group 1: Offering Details - The common stock offering is being managed by Goldman Sachs & Co. LLC, Jefferies, Leerink Partners, and Guggenheim Securities [2]. - The offering is part of a broader strategy that includes a concurrent offering of $300 million in Convertible Senior Notes due 2033, with an option for initial purchasers to buy an additional $45 million [4]. - The common stock offering will be made under a shelf registration statement filed with the SEC, which became effective on May 22, 2023 [5]. Group 2: Use of Proceeds - The net proceeds from the common stock offering, along with those from the convertible notes offering, are intended for general corporate purposes, which may include repurchasing a portion of the 2027 convertible senior notes, although no agreements are currently in place for such transactions [3]. - Potential uses of the proceeds may also involve acquiring complementary products, technologies, or businesses [3]. Group 3: Company Overview - Guardant Health is a leading precision oncology company focused on improving patient care and accelerating cancer therapies through advanced testing and analytics [10]. - The company aims to provide critical insights into cancer management, including early detection, monitoring, and treatment selection [10].